NASDAQ: MDAISpectral Ai Inc Stock
$1.82+0.01 (+0.55%)
Updated Jun 18, 2026
MDAI Price
$1.82
Fair Value Price
N/A
Market Cap
$57.92M
52 Week Low
$1.18
52 Week High
$3.21
P/E
-3.64x
P/B
-6.57x
P/S
2.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.93M
Earnings
-$13.88M
Gross Margin
46%
Operating Margin
-75.74%
Profit Margin
-82%
Debt to Equity
-3.01
Operating Cash Flow
-$12M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDAI Overview
Spectral AI, Inc. is an artificial intelligence (AI) firm specializing in AI-driven medical diagnostics. The company's primary goal is to facilitate faster and more accurate treatment decisions in wound care, particularly for patients dealing with burns and diabetic foot ulcers. Among its key products is DeepView, a predictive diagnostic device that delivers an objective and immediate evaluation of a wound's likely healing trajectory to clinicians, prior to any medical treatment or intervention. Spectral AI, Inc. is headquartered in Dallas, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDAI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
MDAI
Ranked#83 of 93
Ranked#83 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $38.68 | A | |
| $26.62 | A |
Be the first to know about important MDAI news, forecast changes, insider trades & much more!
MDAI News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDAI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MDAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MDAI due diligence checks available for Premium users.
Valuation
MDAI fair value
Fair Value of MDAI stock based on Discounted Cash Flow (DCF)
Price
$1.82
Fair Value
-$1.55
Undervalued by
217.38%
MDAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.64x
Industry
20.08x
Market
9.47x
MDAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.57x
Industry
2.95x
MDAI's financial health
Profit margin
Revenue
$4.0M
Net Income
-$3.4M
Profit Margin
-85.5%
MDAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.7M
Liabilities
$26.5M
Debt to equity
-3.01
MDAI's short-term liabilities ($21.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDAI's short-term assets ($15.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$0.0
Financing
-$1.0k
MDAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDAI vs Medical Device Stocks
Spectral Ai Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.